We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+6.5%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$308M
AUM Growth
-$38.9M
Cap. Flow
-$25.7M
Cap. Flow %
-8.35%
Top 10 Hldgs %
52.97%
Holding
98
New
10
Increased
19
Reduced
20
Closed
18

Top Buys

Rank Stock Value
1
IDYA icon
IDEAYA Biosciences
IDYA
+$4.11M
2
ARCT icon
Arcturus Therapeutics
ARCT
+$4M
3
TBIO
Translate Bio, Inc. Common Stock
TBIO
+$2.94M
4
ETNB
89bio
ETNB
+$2.85M
5
ASND icon
Ascendis Pharma A/S
ASND
+$2.16M

Top Sells

Rank Stock Value
1
ARNA
Arena Pharmaceuticals Inc
ARNA
+$11.3M
2
KURA icon
Kura Oncology
KURA
+$5.64M
3
SNDX icon
Syndax Pharmaceuticals
SNDX
+$3.92M
4
CGEN icon
Compugen
CGEN
+$3.73M
5
AKBA icon
Akebia Therapeutics
AKBA
+$3.69M

Sector Composition

Rank Sector Weight
1 Healthcare 83.1%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRSN
26
DELISTED
Mersana Therapeutics
MRSN
$2.84M 0.92%
6,111
-4,696
-43% -$2.37M
ETNB
27
DELISTED
89bio
ETNB
$2.83M 0.92%
110,478
+90,000
+439% +$2.85M
LQDA icon
28
Liquidia Corp
LQDA
$8.07B
$2.83M 0.92%
575,000
+25,000
+5% +$145K
OTIC
29
DELISTED
Otonomy, Inc.
OTIC
$2.79M 0.91%
689,100
+219,965
+47% +$829K
BEAT
30
DELISTED
BioTelemetry, Inc.
BEAT
$2.76M 0.9%
60,500
– –
VKTX icon
31
Viking Therapeutics
VKTX
$3.9B
$2.62M 0.85%
450,900
– –
KALV
32
DELISTED
KalVista Pharmaceuticals
KALV
$2.62M 0.85%
208,054
-14,398
-6% -$180K
TBIO
33
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$2.6M 0.84%
+190,930
New +$2.94M
ARAY icon
34
Accuray
ARAY
$35.8M
$2.58M 0.84%
1,074,300
+400,000
+59% +$933K
BCRX icon
35
BioCryst Pharmaceuticals
BCRX
$2.38B
$2.57M 0.84%
749,051
+5,000
+0.7% +$21.4K
STIM icon
36
Neuronetics
STIM
$165M
$2.41M 0.78%
495,772
– –
KDMN
37
DELISTED
Kadmon Holdings, Inc.
KDMN
$2.21M 0.72%
563,564
+10,000
+2% +$42K
SPPI
38
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$2.1M 0.68%
+514,891
New +$1.96M
LITS
39
Lite Strategy Inc
LITS
$32.8M
$2.08M 0.68%
33,300
+30,550
+1,111% +$1.84M
CGEN icon
40
Compugen
CGEN
$221M
$1.87M 0.61%
115,202
-227,844
-66% -$3.73M
ISEE
41
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$1.82M 0.59%
322,500
-35,000
-10% -$167K
BLUE
42
DELISTED
bluebird bio
BLUE
$1.63M 0.53%
2,337
– –
SNDX icon
43
Syndax Pharmaceuticals
SNDX
$1.79B
$1.52M 0.49%
102,713
-257,287
-71% -$3.92M
ALEC icon
44
Alector
ALEC
$219M
$1.48M 0.48%
140,000
– –
HARP
45
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$1.45M 0.47%
8,512
– –
JNJ icon
46
Johnson & Johnson
JNJ
$621B
$1.4M 0.45%
9,400
– –
ALPN
47
DELISTED
Alpine Immune Sciences Inc
ALPN
$1.3M 0.42%
+148,260
New +$1.36M
RCUS icon
48
Arcus Biosciences
RCUS
$3.66B
$1.24M 0.4%
72,100
– –
LRMR icon
49
Larimar Therapeutics
LRMR
$433M
$1.2M 0.39%
79,155
-47,106
-37% -$596K
KURA icon
50
Kura Oncology
KURA
$839M
$1.2M 0.39%
39,019
-255,241
-87% -$5.64M
1
2
3 4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
DBG
De Burlo Group Boston, Massachusetts $441M AUM 21.21% 1-Year Est. Return
SPT
Siemens Pension Trust Munich Germany, Germany $437M AUM 183.71% 1-Year Est. Return

DAFNA Capital Management's Q3 2020 Portfolio in Review

As of Q3 2020, DAFNA Capital Management held 98 positions worth $308M, down 11% from $347M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

DAFNA Capital Management withdrew a net $25.7M in Q3 2020, closing 18 positions and reducing 20 holdings. Its most notable exit was Mirati Therapeutics, Inc. Common Stock, an estimated $2.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 88% a quarter earlier, followed by Financials.

Against the trend, DAFNA Capital Management opened a new position in IDEAYA Biosciences worth $4.17M.

  • DAFNA Capital Management's largest Q3 2020 buy was IDEAYA Biosciences: 331,661 shares worth $4.17M.
  • DAFNA Capital Management added most to Arcturus Therapeutics in Q3 2020, an estimated $4M increase.
  • DAFNA Capital Management's biggest Q3 2020 reduction was Arena Pharmaceuticals Inc, cutting an estimated $11.3M.
  • DAFNA Capital Management fully exited Mirati Therapeutics, Inc. Common Stock in Q3 2020, selling an estimated $2.5M.
  • DAFNA Capital Management's ten largest holdings make up 53% of its $308M portfolio in Q3 2020.
  • DAFNA Capital Management opened 10 new positions and closed 18 in Q3 2020.
  • DAFNA Capital Management's portfolio value fell 11% quarter-over-quarter to $308M.

Based on DAFNA Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.